Abstracts

BICTEGRAVIR CONCENTRATIONS AND VIROLOGIC RESPONSES IN PLWH RECEIVING 1HP FOR LTBI

One-month regimen of daily rifapentine (600 mg) plus isoniazid (300 mg) (1HP) is an attractive preventive strategy for PLWH with latent TB infection (LTBI). However, the optimal integrase strand transfer inhibitor-based regimens in combination with 1HP remain unknown. We aimed to assess the completion rate, bictegravir (BIC) trough concentration, cytokine profile, and virologic response in…

A CLUSTER RANDOMIZED TRIAL OF CONTACT TRACING IN HOUSEHOLDS OF INDEX PATIENTS WITH TB

Household contact tracing and investigation for tuberculosis (TB) is recommended, but has not been widely implemented in high HIV-prevalence settings due to uncertainty over effectiveness and the costs of conducting home visits. Intensive HIV/TB screening with appropriate action could reduce household TB transmission and mortality. Index TB patients in two health districts of South Africa…

HEPATOCELLULAR CARCINOMA AND HBV VIREMIA IN HIV/HBV-COINFECTED PERSONS IN NA-ACCORD

Chronic hepatitis B (HBV) is the predominant cause of hepatocellular carcinoma (HCC) worldwide. Although HBV coinfection is common in HIV, the determinants of HCC in HIV/HBV coinfection are poorly characterized. We examined the incidence and predictors of HCC in a multi-cohort study of HIV/HBV-coinfected individuals. We examined all HIV/HBV-coinfected persons (defined by positive HBV surface…

UPRISING CIRCULATION OF HBV-COMPLEX PROFILES WITH HBsAg VACCINE-ESCAPE MUTATIONS

Vaccine-escape mutations can alter HBsAg recognition by antibodies thus challenging vaccine efficacy, promoting immunosuppression-driven HBV-reactivation and impairing HBsAg detection by immunoassays. Limited information is available on the circulation of vaccine-escape mutations, single or in complex mutational profiles, over time and their impact on serological parameters in the setting of HBV genotype-D. This study includes HBsAg…

BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING

The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing COVID-19. BLAZE-2 is…

BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS

Patients with underlying medical conditions have a greater risk of developing severe COVID-19. Unlike vaccine-derived immunity which develops over time, administration of neutralizing monoclonal antibodies is an immediate, passive humoral immunotherapy, with the potential to reduce disease progression, emergency room visits, hospitalizations, and death. In this phase 3 portion of the BLAZE-1 trial, a high-risk…